Eli Lilly announced an agreement to acquireVersanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases for $1.925B in cash.
Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with semaglutide in adults who are overweight or obese.
Combining incretins with bimagrumab has the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people living with obesity and obesity-related complications.
Gilead Sciences headquarters in Silicon Valley. Gilead’s HIV drug Sunlenca (lenacapavir) gained FDA approval in 2022. Credit: Sundry Photography via Shutterstock. Public figures, scientists, medical
Almost a quarter of US children with symptoms of a brain injury or concussion are not checked for the condition, with younger children particularly likely
Eli Lilly Acquires Obesity Drug Maker Versanis for $1.9B – M&A
by Fred Pennic Leave a Comment
What You Should Know:
Opinion | Closing Gender-Based Disease Disparities Starts in the Lab
Despite the fact men have lower life expectancy than women and are at a higher risk of developing serious health conditions like heart disease and
Gilead urged to improve access to HIV drug by public figures and celebrities – Pharmaceutical Technology
Gilead Sciences headquarters in Silicon Valley. Gilead’s HIV drug Sunlenca (lenacapavir) gained FDA approval in 2022. Credit: Sundry Photography via Shutterstock. Public figures, scientists, medical
Study highlights oversight in childhood brain injury checks
Almost a quarter of US children with symptoms of a brain injury or concussion are not checked for the condition, with younger children particularly likely